CKD provides a tremendous opportunity for upcoming therapies specific to CKD such asMAbs, stem cell-based and RNA-based therapies, which reverses disease course or slow down kidney deterioration.
Boston, MA, May 11, 2015 –(PR.com)– Chronic Kidney Disease (CKD) Pipeline Analysis gives comprehensive insight on the various drugs being developed for the treatment of CKD. The report covers all the drugs being developed in various phases (Discovery, Preclinical, Clinical & Marketing). The pipeline focuses on novel pharmacologic drugs & regenerative medicines covering small molecules, monoclonal antibodies, stem cell therapies and RNA-based therapeutics, but excludes symptom relief drugs. The report also covers some of the hot targets in research for CKD treatments.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the CKD Drug market. The report also provide strategic insights on medicines that are likely to have an impact on CKD treatment space and potentially alter standards of care in CKD in the foreseeable future.
Current therapies are not effective and more than half of patients gradually face severe renal and cardiovascular complications, hence it provides a tremendous opportunity for upcoming therapies specific to CKD such asMAbs, stem cell-based and RNA-based therapies, which reverses the disease course or slows down kidney deterioration.
IQ4I Research & Consultancy Pvt. Ltd.